Cagrilintide
About
About Cagrilintide
Cagrilintide is a long-acting amylin analog being developed in combination with semaglutide (as CagriSema) for obesity and type 2 diabetes. The CagriSema combination has shown weight loss exceeding 22% in early trials, rivaling surgical outcomes. Amylin complements GLP-1 action through independent satiety pathways. It is not yet approved but represents the next frontier in pharmacological obesity treatment.
Science
Mechanism of Action
Mimics amylin, a pancreatic hormone co-secreted with insulin, to slow gastric emptying, suppress glucagon, and signal satiety through area postrema receptors — pathways distinct from and additive to GLP-1.
Dosing
Typical Protocol
0.3–2.4 mg subcutaneous injection once weekly; currently in Phase III trials as monotherapy and in CagriSema combination.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
No verified providers offering Cagrilintide yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering Cagrilintide.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.